Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

European Commission Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

November 19th 2025

The European Commission has approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma.

FDA Approves Selumetinib for Adult NF1-Associated Plexiform Neurofibromas

November 19th 2025

The FDA approved selumetinib for the treatment of adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

November 18th 2025

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Dr Masserelli on the Clinical Presentation and Management of LEMS in SCLC

November 18th 2025

Erminia Massarelli, MD, PhD, MS, discusses the clinical presentation and management of Lambert–Eaton myasthenic syndrome in the context of small cell lung cancer.

FDA Awards Orphan Drug Designation to ZEN-3694 for NUT Carcinoma

November 18th 2025

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

FDA Grants Fast Track Designation to FOG-001 for Desmoid Tumors

November 14th 2025

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management

November 14th 2025

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.

FDA Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes

November 13th 2025

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis

November 13th 2025

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs

November 13th 2025

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

FDA Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia

November 13th 2025

Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.

MB-105 Receives FDA RMAT Designation in CD5+ R/R T-Cell Lymphoma

November 13th 2025

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Community Administration of Bispecific Antibodies in Myeloma Hinges on Consensus and Guidance

November 13th 2025

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Emerging ADC Data and Combination Strategies Are Set to Redefine First-Line TNBC Management

November 12th 2025

Joyce O'Shaughnessy, MD, discusses ways that data with sacituzumab govitecan and Dato-DXd may shift treatment standards for patients with mTNBC.

Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma

November 12th 2025

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC

November 12th 2025

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

Sequential CAR T-Cell Therapy and ASCT Yields Durable Remissions in Ph-Negative B-ALL

November 12th 2025

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma

November 11th 2025

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy

November 10th 2025

Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.

Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management

November 10th 2025

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.